orlistat (Xenical)

Subscribe to Selected New Research on orlistat

456 relevant articles (98 outcomes, 150 trials/studies) found for this Drug

Description: isolated from Streptomyces toxytricini; inhibits 3C protease, viral

Also Known As:

Xenical; tetrahydrolipstatin; 1-((3-hexyl-4-oxo-2-oxetanyl)methyl)dodecyl-2-formamido-4-methylvalerate; Alli; GlaxoSmithKline brand of orlistat; Hoffmann-La Roche brand of orlistat; Roche brand of orlistat; THLP; L-Leucine, N-formyl-, 1-((3-hexyl-4-oxo-2-oxetanyl)methyl)dodecyl ester, (2S-(2alpha(R*),3beta))-

Relationship Network

Drug Context: Research Results

Organic Chemicals: 40

Lactones: 133

orlistat: 456

Experts

1.	Elisaf, M S: 5 articles (07/2008 - 12/2005)
2.	Filippatos, T D: 5 articles (07/2008 - 12/2005)
3.	Kiortsis, D N: 5 articles (07/2008 - 12/2005)
4.	Rissanen, A: 4 articles (01/2003 - 01/2000)
5.	Hauptman, J: 4 articles (04/2001 - 02/2000)
6.	Tselepis, A D: 3 articles (07/2008 - 08/2007)
7.	Liberopoulos, E N: 3 articles (06/2008 - 12/2005)
8.	Anderson, James W: 3 articles (08/2007 - 07/2002)
9.	Haddock, C K: 3 articles (10/2006 - 12/2003)
10.	Foreyt, J P: 3 articles (10/2006 - 12/2003)

Related Diseases

1.	Weight Loss (Weight Reduction) 01/01/1998 - "Orlistat, an inhibitor of pancreatic lipases, has proven effective for weight reduction in obese patients" 01/01/2006 - "The weight loss was significantly greater in the orlistat group than in the placebo group for the entire study period (P < 0.001)" 12/01/2005 - "RESULTS: Orlistat-treated patients achieved significantly greater weight loss at the study end than placebo-treated patients (-5.4 vs. -2.4 kg; P<0.0001)" 01/01/2003 - "In randomized, controlled trials of up to 2 years' duration, orlistat plus a hypocaloric diet produced significantly greater weight loss than placebo (P < 0.001)" 10/01/2000 - "In a series of 1- and 2-yr randomized, placebo-controlled trials of obese subjects, treatment with orlistat in combination with a mildly calorie-restricted diet consistently produced significantly greater mean weight loss than diet alone" Get all the results and reference details, order at left...
2.	Obesity 01/01/2006 - "CONCLUSION: Xenical is beneficial for patients with DM-2 and obesity because it improves metabolic processes." 01/01/2002 - "Efficacy of orlistat in the treatment of constitutional-alimentary obesity in patients with high risk of cardiovascular complications]" 01/01/2000 - "Several obesity-related risk factors improved significantly more with orlistat treatment than with placebo" 10/01/1999 - "In a study of patients with obesity associated with type 2 diabetes, patients treated with orlistat lost more weight and had improved serum lipid profiles compared with placebo recipients" 07/01/2002 - "OBJECTIVE: To study the safety, tolerability, and potential efficacy of orlistat in adolescents with obesity and its comorbid conditions" Get all the results and reference details, order at left...
3.	Overweight 01/01/2003 - "CONCLUSION: Adding orlistat as a pharmacological treatment to conventional diabetes and weight management approaches seems to be a cost-effective treatment option for overweight and obese patients with type 2 diabetes." 08/01/2006 - "Effect of orlistat in overweight poorly controlled Chinese female type 2 diabetic patients: a randomised, double-blind, placebo-controlled study." 05/01/2005 - "METHODS: Data from seven randomized controlled clinical trials of orlistat in overweight and obese patients with type 2 diabetes were pooled" 05/01/2002 - "During the past several years, clinical trials have been completed concerning the use of orlistat in the treatment of overweight or obese patients with DM-2" 11/01/1996 - "To determine the metabolic profile of minimally absorbed orlistat in obese/overweight patients, an open-label, single-dose study was performed in eight obese/overweight volunteers between 23 and 68 years of age" Get all the results and reference details, order at left...
4.	Body Weight (Weight, Body) 04/01/1998 - "RESULTS: Orlistat resulted in a significantly greater mean loss of body weight than observed in the placebo group" 04/01/2005 - "The aim of this study was to assess safety, tolerability and efficacy of orlistat treatment in comparison with placebo in the reduction of body weight in obese subjects and the related cardiovascular risk factors" 01/01/2003 - "The results of this study demonstrate that orlistat improved endothelial function, weight, body mass index and systolic and diastolic blood pressure in young women." 11/01/2006 - "There are a number of trials that demonstrate the benefits of orlistat over placebo for reducing body weight and improving other health parameters" 03/01/2005 - "A trial of orlistat (three months) was commenced, after intensive dietary counselling, that reduced her body weight by 1.5 kg (2% reduction, BMI 41.3)" Get all the results and reference details, order at left...
5.	Insulin Resistance 10/01/2007 - "Insulin resistance index and malonyl dialdehyde levels improved significantly after orlistat therapy, whereas HbAic remained unchanged" 10/01/2005 - "Noninvasive hemodynamic parameters including arterial compliance were measured using radial artery pulse wave analysis, at the beginning and 1 month after taking the last dose of Orlistat, and insulin resistance was calculated using HOMA score" 05/01/2004 - "OBJECTIVE: Orlistat leads to improved glycemic control in obese type 2 diabetic patients, which is attributed to decreased insulin resistance associated with weight loss" 04/01/2008 - "CONCLUSION(S): Orlistat administration, combined with diet, for 24 weeks, resulted in significant weight loss and improvement of insulin resistance in obese women, with or without PCOS" 01/01/2004 - "Effects of equal weight loss with orlistat and placebo on body fat and serum fatty acid composition and insulin resistance in obese women." Get all the results and reference details, order at left...
105 Diseases and 456 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	sibutramine (Meridia)
2.	Glucose (Dextrose)
3.	Insulin (Novolin)
4.	Cholesterol
5.	orlistat (Xenical)
6.	Metformin (Glucophage)
7.	Lipoproteins (Lipoprotein)
8.	HDL Cholesterol
9.	LDL Cholesterol
10.	Acarbose
145 Drugs and Important Bio-Agents and 298 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Kidney Transplantation
2.	Phototherapy (Light Therapy)
3.	Bariatric Surgery
4.	Reducing Diet
5.	Fat-Restricted Diet (Diet, Fat Restricted)
19 Therapies and Procedures and 38 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>